Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Sunovion
>
Lunesta going generic - - OUCH!
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3976645"]Why in the world would any MCO or patient want to pay for Lunesta when at the very LEAST they could try this first..... With Lun being approx 60% of the company income you are all screwed when another generic hits the mkt. </p><p><br /></p><p>The US Food and Drug Administration (FDA) has allowed Actavis to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5mg CIV. </p><p><br /></p><p><br /></p><p>The company has already started distribution of the Zolpidem Tartrate Extended-Release Tablets, the generic equivalent of Ambien CR.</p><p><br /></p><p>Sanofi-aventis' Ambien CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.</p><p><br /></p><p>Actavis CEO Doug Boothe said the approval of Zolpidem ER Tablets 12.5 mg enables Actavis to offer both strengths to meet the needs of our customers.</p><p><br /></p><p>"This approval also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace to help improve patient access to pharmaceuticals," Boothe said.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3976645"]Why in the world would any MCO or patient want to pay for Lunesta when at the very LEAST they could try this first..... With Lun being approx 60% of the company income you are all screwed when another generic hits the mkt. The US Food and Drug Administration (FDA) has allowed Actavis to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5mg CIV. The company has already started distribution of the Zolpidem Tartrate Extended-Release Tablets, the generic equivalent of Ambien CR. Sanofi-aventis' Ambien CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Actavis CEO Doug Boothe said the approval of Zolpidem ER Tablets 12.5 mg enables Actavis to offer both strengths to meet the needs of our customers. "This approval also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace to help improve patient access to pharmaceuticals," Boothe said.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Sunovion
>
Lunesta going generic - - OUCH!
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Sunovion
>
Lunesta going generic - - OUCH!
>